Genetic Variations of NAT2 and CYP2E1 and Isoniazid Hepatotoxicity in a Diverse Population

• Dye C , ScheeleS, DolinP, PathaniaV, RaviglioneMC: Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.JAMA282 , 677–686 (1999).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM , WangL, ElwoodRK: Tuberculosis: control of the disease among aboriginal people in Canada.CMAJ162 , 351–355 (2000).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM : Optimizing tuberculosis control in the inner city.CMAJ160 , 821–822 (1999).
   PubMed Web of Science ®Google Scholar
• Hernandez E , KumimotoD, WangL et al.: Predictors for clustering among TB cases in Vancouver: a four year molecular epidemiology study.CMAJ167 , 349–352 (2002).
   PubMed Web of Science ®Google Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb. Mortal. Wkly Rep.49(RR06) , 1–54 (2000).
   PubMedGoogle Scholar
• Durand F , JebrakG, PessayreD, FournierM, BernuauJ: Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.Drug Saf.15 , 394–405 (1996).
   PubMed Web of Science ®Google Scholar
• Dossing M , WilckeJT, AskgaardDS, NyboB: Liver injury during antituberculosis treatment; an 11-year study.Tuber. Lung Dis.77 , 335–340 (1996).
   PubMedGoogle Scholar
• Nolan CM , GoldbergSV, BuskinSE: Hepatotoxicity associated with isoniazid preventive therapy; a 7-year survey from public health tuberculosis clinic.JAMA281 , 1014–1018 (1999).
   PubMed Web of Science ®Google Scholar
• Farrell GC : Drug-induced acute hepatitis. In: Drug-induced liver disease. Farrell GC (Ed.). Churchill Livingstone, Edinburgh, 247–299 (1994).
   Google Scholar
• Zimmerman HJ : Hepatic injury from the treatment of infectious and parasitic disease. In: Hepatotoxicity. Zimmerman HJ (Ed.). Lippincott Williams & Wilkins, PA, USA, 589–637 (1999).
   Google Scholar
• Schaberg T , Gialdroni-GrassiG, HuchonG, LeophonteP, ManresaF, WoodheadM: An analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections. The European Study Group of Community Acquired Pneumonia (ESOCAP) of the European Respiratory Society.Thorax51 , 1017–1022 (1996).
   PubMed Web of Science ®Google Scholar
• Hwang SJ , LeeSD, LiCP, LuRH, ChanCY, WuJC: Clinical Study of cryoglobulinaemia in Chinese patients with chronic hepatitis C.J. Gastroenterol. Hepatol.12 , 513–517 (1997).
   PubMed Web of Science ®Google Scholar
• Pande JN , SinghSP, KhilnaniGC, KhilnaniS, TandonRK: Risk factors for hepatotoxicity from antituberculosis drugs: a case–control study.Thorax.51 , 132–136 (1996).
   PubMed Web of Science ®Google Scholar
• Yee D , ValiquetteC, PelletierM, ParisienI, RocherI, MenziesD: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.Am. J. Respir. Crit. Care Med.167 , 1472–1477 (2003).
   PubMed Web of Science ®Google Scholar
• Steele MA , BurkRF, DesPrezRM: Toxic hepatitis with isoniazid and rifampin a meta-analysis.Chest99 , 465–471 (1991).
   PubMed Web of Science ®Google Scholar
• Saram GR , ImanuelC, KailasamS, NarayanaASL, VenkatesanP: Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.Am. Rev. Respir. Dis.133 , 1072–1075 (1986).
   PubMedGoogle Scholar
• Mitchell JR , ThorgeissonUP, BlackM et al.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites.Clin. Pharmacol Ther.18 , 70–79 (1975).
   PubMed Web of Science ®Google Scholar
• Black M , MitchellJR, ZimmermanHJ, IshakKG, ElperGR: Isoniazid-associated hepatitis in 114 patients.Gastroenterology69 , 289–302 (1975).
   PubMed Web of Science ®Google Scholar
• Ryan DE , RamanathanL, IidaS et al.: Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid.J. Biol. Chem.260 , 6385–6393 (1985).
   PubMed Web of Science ®Google Scholar
• Parkin DP , VandenplasS, BothaFJ et al.: Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.Am. J. Respir. Crit. Care Med.155 , 1717–1722 (1997).
   PubMed Web of Science ®Google Scholar
• Huang YS , ChernHD, SuWJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Hepatology35 , 883–889 (2002).
   PubMed Web of Science ®Google Scholar
• Ohno M , YamaguchiI, YamamotoI et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.Int. J. Tuberc. Lung Dis.4 , 256–261 (2000).
   PubMed Web of Science ®Google Scholar
• Chen B , LiJH, XuYM, WangJ, CaoXM: The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoiazid in Chinese pulmonary tuberculosis patients.Clin. Chim Acta.365 , 104–108 (2005).
   PubMed Web of Science ®Google Scholar
• Vuilleumier N , RossierMF, ChiappeA et al.: CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.Eur. J. Clin. Phamacol.62 , 423–429 (2006).
   PubMedGoogle Scholar
• Roy PD , MajumderM, RoyB: Pharmacogenomics of anti-TB drugs-related hepatotoxicity.Pharmacogenomics9 , 311–321 (2008).
   PubMed Web of Science ®Google Scholar
• Singh J , GargPK, ThakurVS, TandonRK: Anti tubercular treatment induced hepatotoxicity: does acetylator matter?Indian J. Physiol. Pharmacol.39 , 43–46 (1995).
   PubMedGoogle Scholar
• Yuliwulandari R , SachrowardiQ, NishidaN et al.: Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.J. Hum. Genet.53 , 201–209 (2007).
   PubMed Web of Science ®Google Scholar
• Stephens EA , TaylorJA, KaplanN et al.: Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African–Americans, European–Americans and Taiwanese.Pharmacogenetics4 , 185–192 (1994).
   PubMedGoogle Scholar
• Huang YS , ChernHD, SuWJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.Hepatology37 , 924–930 (2003).
   PubMed Web of Science ®Google Scholar
• Ozer J , RatnerM, ShawM, BaileyW, SchomakerS: The current state of serum biomarkers of hepatotoxicity.Toxicology245 , 194–205 (2008).
   PubMed Web of Science ®Google Scholar
• Benichou C : Criteria of drug-induced liver disorders: report of an international consensus meeting.J. Hepatol.11 , 272–276 (1990).
   PubMed Web of Science ®Google Scholar
• Danan G , BenichouC: Causality assessment of adverse reactions to drugs – a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.J. Clin. Epidemiol.46 , 1323–1330 (1993).
   PubMed Web of Science ®Google Scholar
• Frazer KA , PachterL, PoliakovA, RubinEM, DubchakI: VISTA: computational tools for comparative genomics.Nucleic Acids Res.32 , 273–279 (2004)
   PubMed Web of Science ®Google Scholar
• Guo H , MooseSP: Conserved noncoding sequences among cultivated cereal genomes identify candidate regulatory sequence elements and patterns of promoter evolution.Plant cell.15 , 1143–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Rozen S , Skaletsky: Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol.132 , 365–386 (2000).
   PubMedGoogle Scholar
• Brooks-Wilson AR , KaurahP, SurianoG et al.: Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.J. Med. Genet.41 , 508–517 (2004).
   PubMed Web of Science ®Google Scholar
• Nickerson DA , TobeVO, TaylorSL: PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing.Nucleic Acids Res.25 , 2745–2751 (1997).
   PubMed Web of Science ®Google Scholar
• Gordon D , AbajianC, GreenP: Consed: a graphical tool for sequence finishing.Genome Res.8 , 195–202 (1998).
   PubMed Web of Science ®Google Scholar
• Barrett JC , FryB, MallerJ, DalyM: Haploview: analysis and visualization of LD and haplotype maps.Bioinformatics21 , 263–265 (2005).
   PubMed Web of Science ®Google Scholar
• Fuselli S , GilmanRH, ChanockSJ et al.: Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity.Pharmacogenomics J.7 , 144–152 (2006).
   PubMed Web of Science ®Google Scholar
• Benjamini Y , HochbergY: Controlling the false discovery rate: a practical and powerful approach to multiple testing.J. R. Stat. Soc. Series B Stat. Methodol.57 , 289–300 (1995).
   Web of Science ®Google Scholar
• Lake SL , LyonH, TantisiraK et al.: Estimation and tests of haplotype-environment interaction with linkage phase is ambiguous.Hum. Hered.55 , 56–65 (2003).
   PubMed Web of Science ®Google Scholar
• Ludwig MZ : Functional evolution of noncoding DNA.Curr. Opin. Genet. Dev.12 , 634–639 (2002).
   PubMed Web of Science ®Google Scholar
• Lee SY , LeeKA, KiCS et al.: Complete sequencing of a genetic polymorphism in NAT2 in the Korean population.Clin. Chem.48 , 775–777 (2002).
   PubMed Web of Science ®Google Scholar
• Cho HJ , KohWJ, RyuYJ et al.: Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.Tuberculosis87 , 551–556 (2007).
   PubMed Web of Science ®Google Scholar
• Sekine A , SaitoS, IidaA et al.: Identification of single-nucleotide polymorphisms (SNPs) of human N-acetyltransferase genes NAT1, NAT2, AANAT, ARD1 and L1CAM in the Japanese population.J. Hum. Genet.46 , 314–319 (2001).
   PubMed Web of Science ®Google Scholar
• Branch RA , AdedoyinA, FryeRF, WilsonJW, RomkesM: In vivo modulation of CYP enzymes by quinidine and rifampin.Clin. Pharmacol. Ther.68 , 401–411 (2000).
   PubMed Web of Science ®Google Scholar
• Douglas JG , McLeodMJ: Pharmacokinetics factors in the modern drug treatment of tuberculosis.Clin. Pharmacokinet.37 , 127–146 (1999).
   PubMed Web of Science ®Google Scholar
• Nishimura Y , KurataN, SakuraiE, YasuharaH: Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities.J. Pharmacol. Sci.96 , 293–300 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma SK : Antituberculosis drugs and hepatotoxicity.Infect. Genet. Evol.4 , 167–170 (2004).
   PubMed Web of Science ®Google Scholar
• Baldan HM , De Rosa HJ, Brunetti IL, Ximenes VF, Machado RG: The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in Rats. Biopharm. Drug Dispos.28 , 409–413 (2007).
   PubMed Web of Science ®Google Scholar
• Zand R , NelsonSD, SlatteryJT et al.: Inhibition and induction of cytochrome P4502E1-catalysed oxidation by isoniazid in humans.Clin. Pharmacol. Ther.54 , 142–149 (1993).
   PubMed Web of Science ®Google Scholar
• Kubota R , OhnoM, HasunumaT, IijimaH, AzumaJ: Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.Eur. J. Clin. Pharmacol.63 , 927–933 (2007).
   PubMed Web of Science ®Google Scholar
• Cascorbi I , DrakoulisN, BrockmollerJ, MaurerA, SperlingK, RootsI: Aryamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.Am. J. Hum. Genet.57 , 581–592 (1995).
   PubMed Web of Science ®Google Scholar
• Donald PR , ParkinDP, SeifartHI et al.: The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.Eur. J. Clin. Phamacol.63 , 633–639 (2007)
   PubMed Web of Science ®Google Scholar
• Lucas D , MenezC, GirreC et al.: Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects.Pharmacogenetics5 , 298–304 (1995).
   PubMedGoogle Scholar
• Powell H , KitteringhamNR, PirmohamedM, SmithDA, ParkBK: Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype.Pharmacogenetics8 , 411–421 (1998).
   PubMedGoogle Scholar

▪ Websites

• Vista homepage http://genome.lbl.gov/vista/index.shtml
   Google Scholar
• VISTA browser (database on the Internet), CA, USA http://pipeline.lbl.gov/cgi-bin/gateway2 Updated March 2006
   Google Scholar
• UCSC genome browser (database on the Internet), CA, USA www.genome.ucsc.edu/cgi-bin/hgGateway Updated March 2006
   Google Scholar
• In silico PCR (database on the Internet), Kyushu, Japan http://qsnp.gen.kyushu-u.ac.jp/genome/InSilicoPCR.html Updated December 2006
   Google Scholar
• Arylamine N-Acetyltransferase (NAT) Nomenclature http://louisville.edu/medschool/pharmacology/NAT.html
   Google Scholar